VX-670
RNA / oligonucleotide
Evidence outlook
Mid-stage studies underway, no completed readout
Phase 2 studies are registered but none has completed a readout, so no evidence signal is assigned yet. The first graded signal arrives with a completed confirmatory readout.
How the evidence outlook works ↗
Featured trials
The studies most instrumental to this drug's clinical progression, individually graded on design and result. The complete registry, including every study not featured here, is listed below.
| Trial | Phase | Endpoint | Key result | Signal | Source |
|---|---|---|---|---|---|
NCT06185764 NCT06185764 · Myotonic Dystrophy Type 1 Registry: NCT06185764 | 1/2 | Parts A and B: Safety and Tolerability as Assessed by Number of Participants With Adverse Events (AEs) (Part A: From Baseline up to Day 42; Part B: From Baseline and up to Day 168) 2027-02-02 | In progress: results expected 2 Feb 2027 | not yet graded | link ↗ |
View 1 more trial
NCT06926621 NCT06926621 · Myotonic Dystrophy Type 1 Registry: NCT06926621 | 2 | Safety and Tolerability as Assessed by Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs) (From Day 1 up to Week 108) 2029-01-30 | In progress: results expected 30 Jan 2029 | not yet graded | link ↗ |
All registered studies
Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase.
Phase 2 (1)
What this study did
Phase 1/2 (1)
What this study did
Competitive landscape
This drug's own stage for Myotonic Dystrophy Type 1: Phase 2. Competitors below are sorted furthest-along first.
| Drug | Stage | Modality | Mechanism | Evidence signal | Reported efficacygraded featured trials | |
|---|---|---|---|---|---|---|
| VX-670: this drug | Phase 2 | RNA / oligonucleotide | DMPK CUG-repeat RNA | not yet graded | No reviewed efficacy summary in this indication | |
| Delpacibart Etedesiran | Phase 3 | RNA / oligonucleotide | DMPK | not yet graded | No reviewed efficacy summary in this indication | |
| Pitolisant (Wakix) | Phase 2 | Small molecule | Histamine H3 receptor (antagonist / inverse agonist) | not yet graded | No reviewed efficacy summary in this indication | |
| SAR446268 | Phase 1/2 | Gene therapy / editing | DMPK | not yet graded | No reviewed efficacy summary in this indication | |
| SRP-1003 | Phase 1/2(overall) | RNA / oligonucleotide | DMPK (dystrophia myotonica protein kinase) | not yet graded | No reviewed efficacy summary in this indication |
Upcoming events
(2 total)
Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.
Follow VX-670 to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.
Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.